Sylvester Comprehensive Cancer Center

  • LOXO-BTK-18001 - Alencar, Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    Coordinator:

    IRB: 20190647

    SDG: Lymphoma
    Disease Site(s):

    Leukemia, Other,Lymphoid Leukemia,Non-Hodgkin Lymphoma

    Sponsor: LOXO ONCOLOGY

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

    Eligibility Criteria - NCT03740529 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190961 - Bradley Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:

    IRB: 20190961

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other,Leukemia, not otherwise specified,Myeloid and Monocytic Leukemia,Other Hematopoietic

    Sponsor: FORTY SEVEN, INC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination with Azacitidine in Patients with Hematological Malignancies

    Eligibility Criteria - NCT03248479 *This information has been extracted from " www.clinicaltrials.gov"

  • SEL 120 - Bradley, Terrence

  • Investigator:
    Terrence Bradley
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20191267

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other,Myeloid and Monocytic Leukemia,Other Hematopoietic

    Sponsor: SELVITA

    Enrolling Sites:

    Sylvester

    Title:

    A Phase Ib Study of SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

    Eligibility Criteria - NCT04021368 *This information has been extracted from " www.clinicaltrials.gov"

  • ATRC-101-A01 - Chandhok, Namrata

  • Investigator:
    Namrata Chandhok
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20200937

    SDG: Leukemia/heme
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: Aptose Biosciences

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1a/b Trial of CG-806 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes

    Eligibility Criteria - NCT03893682 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200056 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20200056

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid

    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester

    Title:

    A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor

    Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201131 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20201131

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Stomach

    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 Open-label, Multicenter Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate (Repaglinide) in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)

    Eligibility Criteria - NCT04530981 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191308 - Feun Lynn

  • Investigator:
    Lynn Feun
    RCname Email

    Coordinator:
    RCemailImg Silvia Garcia
    RCphone +1 (305) 2433009

    IRB: 20191308

    SDG: Cutaneous Malignancies
    Disease Site(s):

    Melanoma, skin

    Sponsor: INXMED

    Enrolling Sites:

    Sylvester

    Title:

    A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects with Metastatic Melanoma

    Eligibility Criteria - NCT04109456 *This information has been extracted from " www.clinicaltrials.gov"

  • REGN5458 - Hoffman, James

  • Investigator:
    James Hoffman
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20190220

    SDG: Myeloma
    Disease Site(s):

    Multiple Myeloma

    Sponsor: REGENERON PHARM INC

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma

    Eligibility Criteria - NCT03761108 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190887 - Huang Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Violeta Milic
    RCphone 305-243-5181

    IRB: 20190887

    SDG: Gynecologic Cancer
    Disease Site(s):

    Lung,Ovary

    Sponsor: MER

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

    Eligibility Criteria - NCT03319628 *This information has been extracted from " www.clinicaltrials.gov"

  • ACE-LY-003 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20180457

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Acerta

    Enrolling Sites:

    Sylvester

    Title:

    ACE-LY-003: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B Cell Non-Hodgkin Lymphoma

    Eligibility Criteria - NCT02180711 *This information has been extracted from " www.clinicaltrials.gov"

  • GO40516 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20180637

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Sylvester

    Title:

    GO40516:An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, and Efficacy Of Mosunetuzumab (BTCT4465A) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma Lymphoma

    Eligibility Criteria - NCT03671018 *This information has been extracted from " www.clinicaltrials.gov"

  • GO40515 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20180638

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Sylvester

    Title:

    GO40515: A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating The Safety, Tolerability, Pharmacokinetics, And Efficacy OfMosunetuzumab (BTCT4465) In Combination With CHOP or CHP-PolatuzumabVedotin In Patients With B-Cell Non-Hodgkin Lymphoma

    Eligibility Criteria - NCT03677141 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191008 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20191008

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma,Non-Hodgkin Lymphoma

    Sponsor: MEI PHARMA

    Enrolling Sites:

    Sylvester

    Title:

    A Three-Arm Study of ME-401 Monotherapy in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL), of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell Non-Hodgkin?s Lymphoma (NHL), and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL

    Eligibility Criteria - NCT02914938 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • RTX-240-01 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200686

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Multiple

    Sponsor: Rubius Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB

    Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191009 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:

    IRB: 20191009

    SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Bones and Joints,Lip, Oral Cavity and Pharynx

    Sponsor: HOOKIPA PHARMA

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I/II Study of TheraT® Vector(s) Expressing HumanPapillomavirus 16 Positive (HPV 16+) Specific Antigens inPatients with HPV 16+ Confirmed Cancers

    Eligibility Criteria - NCT04180215 *This information has been extracted from " www.clinicaltrials.gov"

  • Tbio-6517-ITu-001 - Pimentel, Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20200277

    SDG: Colorectal Cancer
    Disease Site(s):

    Multiple

    Sponsor: TSB

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors

    Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-101 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20180056

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    AMC-101: A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas A Trial of the AIDS Malignancy Consortium (AMC)

    Eligibility Criteria - NCT03220022 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Rodriguez, Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20180802

    SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Breast-Female,Colon,Melanoma, skin

    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester

    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors

    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • DST-2970 - Sharma, Janaki

  • Investigator:
    Janaki Sharma
    RCname Email

    Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200540

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Prostate

    Sponsor: DISPERSOL TECH

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate

    Eligibility Criteria - NCT04291664 *This information has been extracted from " www.clinicaltrials.gov"

  • SPN-00714 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20190673

    SDG: Other
    Disease Site(s):

    Breast,Colon,Esophagus,Kidney,Lung,Other Female Genital,Ovary,Stomach

    Sponsor: MTEM

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors

    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"

  • ATRC-101-A01 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20200938

    SDG: Other
    Disease Site(s):

    Breast,Colon,Lung,Melanoma, skin,Ovary

    Sponsor: Atreca Inc

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination with Other Anticancer Agents in Adults with Advanced Solid Malignancies

    Eligibility Criteria - NCT04244552 *This information has been extracted from " www.clinicaltrials.gov"

  • AG120-C-001 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Alessia Zoso
    RCphone +1 (305) 2432373

    IRB: 20140124

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Agios

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation.

    Eligibility Criteria - NCT02074839 *This information has been extracted from " www.clinicaltrials.gov"

  • H3B-8800-G000-101 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20170778

    SDG: Leukemia/heme
    Disease Site(s):

    Myeloid and Monocytic Leukemia

    Sponsor: H3BIO

    Enrolling Sites:

    Sylvester

    Title:

    H3B-8800-G000-101: An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

    Eligibility Criteria - NCT02841540 *This information has been extracted from " www.clinicaltrials.gov"

  • S17-00978 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20180143

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other

    Sponsor: NYULMC

    Enrolling Sites:

    Sylvester

    Title:

    S17-00978:A Phase Ib/IIa Study Evaluating the Safety and Tolerability ofVitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations

    Eligibility Criteria - NCT03433781 *This information has been extracted from " www.clinicaltrials.gov"

  • 5001 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20180739

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other,Myeloid and Monocytic Leukemia

    Sponsor: Aptevo Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1b Open-Label, Dose-Escalation And Dose-Expansion Study of APVO436 In Patients With Advanced High Risk Leukemias, Including Relapsed or Refractory AML, or High-Grade MDS

    Eligibility Criteria - NCT03647800 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190675 - Watts Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20190675

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other,Myeloid and Monocytic Leukemia

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester

    Title:

    An Open-Label Phase 1b Study of NEROFE, a Novel Hormone-Peptide in Adult Patients with Advanced Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

    Eligibility Criteria - NCT04365179 *This information has been extracted from " www.clinicaltrials.gov"

  • INCB057643 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:

    IRB: 20200314

    SDG: Leukemia/heme
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Incyte Corporation

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced MyeloidNeoplasms

    Eligibility Criteria - NCT04279847 *This information has been extracted from " www.clinicaltrials.gov"